Tirzepatide Coupon: Mounjaro & Zepbound Savings Guide 2026

Tirzepatide savings: distinct Mounjaro and Zepbound programs, current caps and cash terms, insurance questions and compounding limits.

Mounjaro and Zepbound Need Separate Program Checks

The current Mounjaro label includes glycemic control in adults and children aged ten or older with type 2 diabetes and reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. It is not the Zepbound weight-management label. Mounjaro starts at 2.5 mg weekly; increases in 2.5-mg steps require additional glycemic control and at least four weeks at the current dose. The maximum is 15 mg weekly in adults and 10 mg in pediatric patients. Product, indication, presentation and prescription instructions must match.

Zepbound contains the same active ingredient but has its own weight-management and OSA label, presentations and manufacturer savings rules. There is no one unified tirzepatide coupon interchangeable between the brands. Neither mechanism nor the lowest advertised price identifies the right treatment for an individual.

Mounjaro Commercial and Cash Offers

The current Mounjaro single-dose-pen commercial savings card advertises as little as $25 for an eligible covered prescription, with maximum savings of $150 per 28-day fill, $1,950 annually and up to 13 fills. The commercially insured but not-covered offer advertises as low as $499 per 28-day fill, subject to $647 monthly and $8,411 annual savings caps. Government-program beneficiaries are excluded, and an approved-use prescription and other eligibility rules apply. These offers end December 31, 2026 and cannot be assumed to renew or stack with another discount.

Separate LillyDirect Mounjaro self-pay pricing currently displays starting at $499 per month for single-dose pens across listed strengths. The purchase terms require an approved-use prescription and an eligible adult US or Puerto Rico resident; one fill is four pens. There is no insurance reimbursement or deductible/true-out-of-pocket credit under that program; taxes and fees may apply. This is a cash channel, not the commercial savings card and not a guaranteed retail quote.

Zepbound Commercial and Cash Offers

Use the current Zepbound programs for the exact presentation. The covered commercial single-dose-pen card advertises as little as $25 but is limited to $100 savings per 28-day fill, $1,300 annually and up to 13 fills; the not-covered commercial single-dose-pen offer is as low as $499 with its terms. Cash KwikPen offers list $299 at 2.5 mg and $399 at 5 mg; the $449 higher-strength offer requires its purchase and 45-day refill conditions. Commercial-card and cash eligibility are separate, with 2026 expiry and other limits. These are per-prescription quantities, not $25 per injection or one universal coupon for every tirzepatide brand.

Insurance, Patient Assistance and a Useful Quote

Ask the insurer or pharmacy-benefit manager for the exact product’s current formulary status, prior-authorization and step-therapy criteria, required documentation, quantity limits, duration and expected cost. A clinician’s decision that treatment is appropriate and a plan’s decision to cover it are separate. There is no universal approval percentage, A1C cutoff, sequence of medicines, dose-based exemption or turnaround applicable to all plans. For broader online weight-management care, SurpassMD describes its program and assessment process.

If coverage is denied, obtain the written reason and the instructions and deadline for reconsideration or appeal. The prescriber can address the actual missing information or clinical rationale using truthful records; do not invent medication failures, change a diagnosis to obtain coverage or follow a template treatment solely to satisfy an article. HealthCare.gov explains internal appeals and external review. The applicable process and urgency criteria depend on the plan and circumstances; a peer-to-peer review is not a guarantee of approval or a replacement for a formal appeal deadline.

The current Lilly Cares list includes neither Mounjaro nor Zepbound. Do not assume an income-qualified free-tirzepatide program, a universal $250 uninsured price, or a temporary coupon bridge with later insurance reimbursement. Compare the actual program’s restrictions, total quantity, required supplies, fees and ongoing clinical-care costs. For the full bill, our GLP-1 Price Check directory helps compare medication and membership costs.

Compounding, Future Competition and Treatment Choice

Compounded tirzepatide is not FDA-approved Mounjaro, Zepbound or an approved generic equivalent. FDA’s current policy distinguishes patient-specific 503A compounding from 503B outsourcing-facility requirements and does not make a routine copy lawful merely because the brand is expensive. FDA advises using compounded drugs only when an approved medicine cannot meet the patient’s medical need. A pharmacy license, accreditation, review or purity report does not establish an approved product or prove equivalent clinical outcomes. Ask the prescriber and dispensing pharmacy about the actual legal and medical basis, formulation, concentration, instructions and source; avoid research-only products.

Do not budget around unverified generic or biosimilar launch dates or future price reductions. An actual FDA approval and commercial offer are different from a patent forecast. Discuss indication, evidence, tolerability, contraindications, product-specific dosing and access with the clinician; no dose-equivalent universal pounds-lost comparison applies to every tirzepatide and semaglutide product.